argenx is a global, commercial-stage biopharma company developing differentiated therapies for severe autoimmune diseases. Founded in 2008, it is headquartered in Amsterdam and listed on Nasdaq and Euronext Brussels under ARGX.
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Novartis has signed a research partnership and licensing agreement with Unnatural Products valued at up to $1.8 billion to develop macrocyclic peptide therapeutics targeting cardiovascular diseases using AI-driven drug discovery.
Unnatural Products entered a research collaboration and licensing agreement with Novartis worth up to $1.8 billion to develop orally-delivered macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07596849 |
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. |
NOT_YET_RECRUITING | PHASE3 |
| NCT07595653 |
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy |
RECRUITING | |
| NCT07583641 |
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults |
NOT_YET_RECRUITING | PHASE2 |
| NCT07570316 |
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07377396 |
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers |
RECRUITING | PHASE1 |
| NCT07294170 |
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis |
RECRUITING | |
| NCT07287982 |
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy |
RECRUITING | PHASE2 |
| NCT07284420 |
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod |
RECRUITING | PHASE2 |
| NCT07264426 |
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study |
RECRUITING | |
| NCT07194850 |
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) |
RECRUITING | PHASE2/PHASE3 |
